The biotech company said approval of its investigational new drug application for the vaccine, mRNA-1273, would depend on success in the Phase I study that it is currently conducting. That study has completed enrollment of its first three cohorts, totaling 45 healthy volunteers aged 18-55.

LEAVE A REPLY

Please enter your comment!
Please enter your name here